The clinical observation of arsenic trioxide in previously untreated patients of acute promyelocytic leukemia

Objective the clinical effects of arsenic trioxide in previously untreated patients of acute promyelocytic leukemia. Methods As2O3 was given to twenty-two previously untreated patients, and DA regimens were used as maintenance treatment. Continual complete remission and adverse effects were followed. Results complete remission rate was 81.8%. The longest survival time was five years. Conclusions arsenic trioxide is effective in the treatment of APL.